Breast Milk vs Sucrose in Relieving Procedural Pain in Preterm Neonates During Blood Draw by Automated Heel Lance

May 21, 2021 updated by: Pradeep Velumula, Wayne State University

Breast Milk vs 24 % Sucrose in Procedural Pain Relief in Preterm Infants: Randomized Controlled Trial

Skin breaking procedure through an automated heel lancet for blood draws is a common painful procedure in the Neonatal Intensive care unit (NICU). Recurrent pain in preterm neonates is associated with long-term complications. The primary objective of the study is to compare pain scores between two groups (24% sucrose and breast milk) during blood draw using an automated heel lancet in preterm neonates. The investigator conducted a prospective randomized controlled trial in preterm neonates, to compare the pain scores in infants receiving either breast milk or sucrose. Premature Infant pain profile- Revised pain profile is used to assign pain scores. The primary outcome measure is the comparison of pain scores between the two groups.

Study Overview

Status

Completed

Conditions

Detailed Description

Blood draw by automated heel lancet is a common painful procedure in the Neonatal Intensive care units (NICU). The cutaneous sensory receptors on all mucosal and cutaneous surfaces are developed by 20 weeks gestational age (GA) and the neuronal circuits that carry pain stimuli from skin to cerebral cortex are developed by around 26 weeks of GA. Recurrent pain in preterm neonates impacts their postnatal growth, development, is associated with altered pain perception, and increased behavioral responses for future painful procedures.

Oral sucrose is a commonly administered and effective non-pharmacologic intervention used in the NICU for pain relief. There is insufficient evidence on its mechanism of action, minimum effective dose, the effect of repeated doses on long-term neurodevelopmental outcomes, and the consistency in providing pain relief with repeated doses over time. Moreover, the analgesic effect of sucrose is a developmentally transient phenomenon. Another non-pharmacologic intervention studied for pain relief in neonates is breast milk. The analgesic property of breast milk is presumed to be from its sweet taste from lactose, flavor, and odor. Breast milk has high levels of tryptophan, a melatonin precursor which may increase secretion of beta-endorphin, an endogenous opioid.

There is a paucity of data comparing analgesic properties of breast milk and sucrose in preterm neonates, along with insufficient evidence of sucrose as mentioned earlier, The investigator conducted this prospective randomized controlled trial (RCT) comparing sucrose with breast milk for pain relief in preterm neonates.

The primary objective of the study is to compare pain scores between two groups (24% sucrose and breast milk) during blood draw by automated heel lancet, in preterm neonates. The pain scores between the two groups will also be compared at 30 seconds intervals until two minutes post-procedure.

The current study is conducted at Hutzel Women's Hospital and Children's Hospital of Michigan NICU. Institutional Review Board approval was obtained from Wayne State University prior to study initiation. Before the study was initiated, physicians were trained in assessing the PIPP-R pain scale. The pain scores were given by two physicians who were blinded to the treatment arm, at baseline, during, 30-, 60-, 90-, and 120 seconds post-procedure. These scores were given either at the time of the procedure or a video is recorded to be scored later.

Eligible participants were identified and written informed consent was obtained from the parents. The timing and need for a blood draw are decided by the clinical team and are performed by the nurse taking care of the participant. Randomization was done by the pharmacist through a computer-generated program. Participants were randomly assigned to receive either 0.5 ml 24 % sucrose or 2 ml breastmilk, 2 minutes prior to the procedure. On the day of the procedure, the pharmacist sent a closed sealed envelope with a randomization group to the nurse taking care of the participant. Pain scores are given by two physicians during and post-procedure.

Te Investigators collected maternal characteristics of participants like age, prenatal care, race, history of diabetes and hypertension, receipt of antenatal steroids, magnesium, histological diagnosis of chorioamnionitis, mode of delivery, and duration of rupture of membranes. Neonatal characteristics collected include sex, APGAR score at 1 and 5 minutes, birth weight, gestational age, weight on the day of the procedure, postmenstrual age, number of skin pricks prior to the day of the procedure, and adverse events pre-defined as heart rate >240beats/minute or heart rate <80 beats/minute for >20 seconds, oxygen saturation <80 for >20 seconds, no spontaneous respiration for >20 seconds, choking, gagging were collected.

For this non-inferiority trial, the investigators chose the clinically significant difference to be 2 between the median PIPP-R scores during the procedure The investigators required 88 patients (44 in each group) to show that the lower limit of one-sided 95 % CI will be above the non-inferiority limit of -2 for an alpha error of 5% and power of 90 %.

Study Type

Interventional

Enrollment (Actual)

88

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Michigan
      • Detroit, Michigan, United States, 48201
        • Detroit Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 1 month (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. All Infants with gestational age between 30 1/7 and 36 6/7 weeks
  2. Within 30 days of post-natal life
  3. Breast milk is available for the neonate
  4. Scheduled for a blood draw

Exclusion Criteria:

  1. Neonates on intravenous or peroral medications for sedation/analgesia or anti-epileptics
  2. Infants diagnosed with neonatal abstinence syndrome and neonatal encephalopathy
  3. Infants who are critically ill, on assisted ventilation > 2L HFNC and on ionotropic support
  4. Infants with major congenital abnormalities/dysmorphism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Breast Milk
2 ml of Breast milk given one time, two minutes prior to the heel lance
Interventional drug is given to the neonates 2 minutes before the heel lance
OTHER: 24 %Sucrose
0.5 ml sucrose to be given once, two minutes prior to the heel lance
0.5 ml of sucrose given once 2 minutes prior to procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Profile
Time Frame: During the Procedure
Premature Infant Pain Profile- Revised pain profile is used to give pain scores to the participants. Minimum score and maximum scores on the scale are zero and twenty one. The pain scores increases with increasing severity of pain.
During the Procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Profile
Time Frame: Pain scores will be given at 30 seconds interval for 2 minutes, post-procedure
Premature Infant Pain Profile- Revised pain profile is used to give pain scores to the participants.
Pain scores will be given at 30 seconds interval for 2 minutes, post-procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pradeep Velumula, MD, Detroit Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2020

Primary Completion (ACTUAL)

May 7, 2021

Study Completion (ACTUAL)

May 7, 2021

Study Registration Dates

First Submitted

May 17, 2021

First Submitted That Met QC Criteria

May 21, 2021

First Posted (ACTUAL)

May 24, 2021

Study Record Updates

Last Update Posted (ACTUAL)

May 24, 2021

Last Update Submitted That Met QC Criteria

May 21, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1905002251

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Breast Human Milk

Subscribe